Latest Healthcare News

Invion Limited posted a $8.8 million loss for FY25, marking a 56.5% increase, while advancing clinical trials and securing fresh capital. The biotech faces a going concern warning amid ongoing development and funding challenges.

archTIS Limited has reported FY25 results with solid ARR growth and completed a transformative acquisition of Spirion LLC, significantly boosting its US market presence and product suite. The company is raising $20.5 million to fund this expansion and accelerate growth.

WAM Research Limited reported a robust 22.4% growth in its investment portfolio for FY2025, outperforming key ASX indices and declaring a 10 cents per share dividend, partially franked at 60%. The company’s disciplined focus on undervalued growth stocks underpinned strong returns despite market volatility.

NeuroScientific Biopharmaceuticals reports encouraging early clinical results for its StemSmart™ MSC therapy in preventing and treating kidney transplant rejection and injury.

RAM Essential Services Property Fund reported solid FY25 results, highlighting portfolio growth, strategic capital recycling, and a clear transition towards a pure healthcare real estate focus.

RAM Essential Services Property Fund (REP) reported solid FY25 results, maintaining stable occupancy and delivering steady income while progressing its shift to a healthcare-focused REIT. The fund also announced a key board appointment as it looks ahead to further growth.

RAM Essential Services Property Fund (REP) posted a reduced net loss for FY25 alongside stable distributions and extended its debt facility to January 2027, maintaining a focus on essential healthcare and retail properties amid a cautious economic outlook.

BCAL Diagnostics has partnered with Sonic Healthcare Australia to broaden access to its innovative blood-based breast cancer test, BREASTEST plus™, across Sydney. This move formalizes a commercial rollout following successful trials and aims to improve early detection for women with dense breast tissue.

Katana Capital Limited reported a 10.63% gross investment return for the 2025 financial year, surpassing the All Ordinaries index by 1.16%. The fund’s defensive strategy and valuation discipline helped navigate a volatile market environment.

Mach7 Technologies reported a robust FY25 with 16% revenue growth and a strategic pivot towards customer-centric innovation, underpinned by leadership changes and a strong financial position.

Biome Australia Limited has reported its first net profit alongside a 41.6% jump in sales revenue, driven by strong domestic growth and expanding international partnerships.

Mach7 Technologies Limited reported a 16% revenue increase to AUD 33.8 million for FY25, alongside a 22% reduction in net loss, driven by a strategic shift to subscription-based sales and disciplined cost management.